CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
August 10, 2023 16:05 ET
|
CalciMedica
International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS), in India Expansion of team...
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
August 09, 2023 07:30 ET
|
CalciMedica
CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (NASDAQ: CALC), a...
CalciMedica Announces Relisting on Nasdaq
June 12, 2023 07:30 ET
|
CalciMedica
LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening...
CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
June 06, 2023 07:30 ET
|
CalciMedica
Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP Data show that inhibiting Orai1-mediated store-operated...
CalciMedica Expands Executive Team with New Appointments
May 23, 2023 07:30 ET
|
CalciMedica
LA JOLLA, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening...
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
May 15, 2023 08:55 ET
|
CalciMedica
LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening...
CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
March 20, 2023 16:25 ET
|
CalciMedica
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC”- Cash and cash equivalents of approximately $34 million as of merger close expected...
Graybug Announces Name and Trading Symbol Change
March 20, 2023 13:22 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will...
Graybug and CalciMedica Enter into Definitive Merger Agreement
November 21, 2022 18:52 ET
|
Graybug Vision, Inc.; CalciMedica Inc.
– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases ...
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
November 10, 2022 16:59 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on...